Eighth Edition - R.3 - Human Fertilisation & Embryology Authority

Index
see also partner of patient
males, embryo donation by 5.20, 11.25
materials see equipment and materials
maternal age
criteria for four eggs or three embryos 7.4b
criteria for three eggs or two embryos 7.3b
medical devices
CE marked, to be used wherever possible T30(26)
procedures to detail specifications
materials/reagents for
T31(26)
see also equipment and materials
medical history
of donors 11.8–11.10
notification about genetic disease 11.21, 11.22
refusal to give consent for 11.10
welfare of child risk assessment 8.9, 8.10b
medical records, patients’
access to 30.4–30.7
documented procedure 30.5
donors/recipients, to own records 30.5e
person responsible for 30.5c
prompt consideration of applications 30.5b
standard operating procedures
T44(30)
unauthorised, security to prevent 30.6
audit 18.28
consent (recording in records)
identity verification evidence 5.10, 5.11
for legal parenthood 6.10
number of eggs/embryos transferred 5.2b, 7.8b
recording of information provision for 5.15
copy for patients 30.7
four eggs or three embryos
7B
ICSI reasons for using 21.3
storage off site, confidentiality 30.5f
welfare of child assessment 8.18
see also records
medical staff 2.7–210
disclosure of identifying information to 5.27b, 30.18b
for insemination services 2.9
registration and records of 2.7
in training 2.10
training/qualification requirements 2.8, 2.9
medical testing, donors 11.15–11.16
Medicines and Healthcare products
Regulatory Agency (MHRA) 27.8
men, embryo donation by 5.20, 11.25
mental capacity, for consent 5.33
assessment of 5.30
definitions 5.8b
for legal parenthood 6.11b
procedure for obtaining consent 5C, 5.8b, 5.33
to treatment 5C, 5.8b, 5.33
mental incapacity and consent
storage of gametes/embryos 5D, 5.30, 17.14a
treatment/examination without consent 5.23c
metabolomics, embryo selection
T91(10)
micromanipulation procedures,
practitioners competent for 2.20, 2.21
miscarriage risk, information on 7.6a
mismatches of gametes/embryos 27.2b
avoiding 18.1, 18.25, 18.26
risk of 18.25, 18.26
mitochondrial disorders see heritable conditions
multidisciplinary team, embryo testing 2.23, 10.2, 10.10
multiple births
consent for multiple egg/embryo transfer 7.8
complications, risk 7.6a
information provision for
multiple egg/embryo transfer 7.6–7.7
limit on embryo transfer 7B, 7.1–7.5
practical/financial emotional impact 7.6d
risks
evidence of advising patient 7A, 7.8
information provision 7.6
recording consent and 5.2b, 7.8
strategy to minimise
7A
N
near miss, definition 27.4
nonconformities (to procedures)
corrective actions 23.27
inter-laboratory
see inter-centre/inter-laboratory comparisons
notification of HFEA, of heritable condition
in donors 11.22a
number of eggs transferred see egg transfer
number of embryos transferred
see embryo transfer
Nursing and Midwifery Council
2A
nursing staff 2A, 2.11
competencies and evidence for 2.11
qualifications/registration
2A
O
obligations, of centres 32A, 32.1
Authority member/employee entering premises T3(32)
suitable practices
T2(32)
observers, consent to presence 5.25
off-site storage of records 30.5f, 30.6, 31.2
on-call procedures, alarms/monitoring
equipment for cryopreserved gametes/embryos 17.6, 26.4c
oncology patients
counselling arrangements 3.10
storage of gametes 5.31, 17.13
organisation chart 2.4
inclusion in quality manual 23.11c, 23.11d
outcomes of treatment
informing treatment centre, importance 4.2j
Human Fertilisation and Embryology Authority
Index
Version 3.0